Incyte Corporation (LON:0J9P)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 9.66B |
| Revenue (ttm) | 3.42B |
| Net Income (ttm) | 16.46M |
| Shares Out | n/a |
| EPS (ttm) | 0.08 |
| PE Ratio | 586.61 |
| Forward PE | 11.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52 |
| Average Volume | 708 |
| Open | 68.24 |
| Previous Close | 68.61 |
| Day's Range | 67.45 - 68.24 |
| 52-Week Range | 53.61 - 83.54 |
| Beta | 0.68 |
| RSI | 52.69 |
| Earnings Date | Jul 29, 2025 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial numbers in USD Financial StatementsNews
Incyte: New CEO Brings A New Possible Outcome
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Notable Insider Move: William Meury Takes Part In Options Exercise At Incyte, Resulting In $0
Highlighted on June 30, it was unveiled in an SEC filing that Meury, Chief Executive Officer at Incyte (NASDAQ: INCY), executed a significant transaction involving the exercise of company stock optio...
Incyte Stock Gets Relative Strength Rating Lift
A Relative Strength Rating upgrade for Incyte shows improving technical performance. Will it continue?
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2215332012-77883bd9aebd41e886dd23459fedff50.jpg)
Incyte Stock Rises as Pharmaceutical Firm Appoints New CEO
Incyte shares rose Thursday after the drugmaker named Bill Meury its new CEO, effective immediately, to replace the retiring Hervé Hoppenot.
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Incyte stock popped Thursday after the company's board appointed Bill Meury as its new CEO, replacing Herve Hoppenot, who is retiring.
Incyte taps Bill Meury as CEO
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire.
Incyte Says FDA Extended Review Period for Opzelura
Incyte said federal regulators have extended the review period for evaluating its Opzelura cream as a treatment for moderate atopic dermatitis in children aged 2 to 11.
Incyte says FDA delays target action date for ruxolitinib cream
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
Incyte (NASDAQ: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib cream (Opzelura ...
Incyte Lymphoma Treatment Gets FDA Approval
Incyte said it received approval from the Food and Drug Administration for monjuvi, in combination with rituximab and lenalidomide, as a treatment for follicular lymphoma.
Incyte granted FDA label expansion for lymphoma therapy Monjuvi
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD1...
Incyte reports results from blood disorder studies
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses
Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development. Latest Ratings for INCY Full story available on Be...
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Shares of Incyte Corporation (NASDAQ: INCY) rose sharply in today's pre-market trading . QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients w...
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration t...
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025.
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
WILMINGTON, Del.--(BUSINESS WIRE)--Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte rises as it will present new data on thrombocythemia asset at conference
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2025--Multiple Incyte Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted at EHA 2025.
20 stocks primed for rapid growth while trading at half of Nvidia's valuation
When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.
Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs
Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline prospects. Read the full analysis here on Seeking Alpha.